BioSpace News Archive

Business

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights

AmpliPhi Biosciences Corporation announced financial results for the fourth quarter and full year ended December 31, 2017.

March 14, 2018
·
3 min read
Business

Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors

Ardelyx, Inc. reported pipeline highlights and financial results for the fourth quarter and full-year ended December 31, 2017.

March 14, 2018
·
7 min read
Business

Corindus Reports Fourth Quarter and Full Year 2017 Results

Corindus Vascular Robotics Inc. reported financial results for its fourth quarter and year ended December 31, 2017.

March 14, 2018
·
3 min read
Business

NantHealth Reports 2017 Fourth-Quarter and Full-Year Financial Results

NantHealth, Inc. reported financial results for its fourth quarter and full year ended December 31, 2017.

March 14, 2018
·
7 min read
Biotech Bay

Arcus Biosciences Announces Pricing of Initial Public Offering

Arcus Biosciences announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15.00 per share for total gross proceeds of $120,000,000.

March 14, 2018
·
1 min read
Business

Quanterix Corporation Releases Operating Results for Fourth Quarter and Fiscal Year 2017

Quanterix Corporation reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.

March 14, 2018
·
4 min read
WallachBeth Capital, LLC Acts as the Sole Placement Agent for SmartZyme’s Ongoing Series B-1 Offering

WallachBeth Capital, a leading provider of institutional execution services, is acting as the sole placement agent for SmartZyme BioPharma’s Series B-1 preferred-stock round.

March 14, 2018
·
1 min read
Bio NC

Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tenax has regained compliance with the Bid Price Rule and the matter is now closed.

March 14, 2018
·
3 min read
FDA

FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) in Adult Patients with Sialorrhea

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date in Q4 2018, and if approved, has the potential to make Xeomin the first neurotoxin with this indication in the U.S.

March 14, 2018
·
9 min read
BioMidwest

ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich

Oncologists at Leading Swiss Hospital Select MRIdian Linac as Preferred Technology In Competitive European Tender

March 14, 2018
·
4 min read